Evan Seigerman, BMO Capital Markets senior research analyst, joins 'Squawk Box' to discuss the FDA's approval of Eli Lilly's Alzheimer's drug donanemab, how much revenue it could add to Elil LIlly's bottom line, and the details behind the newly approved drug. For access to live and exclusive video from CNBC subscribe to CNBC PRO: [ Ссылка ]
» Subscribe to CNBC TV: [ Ссылка ]
» Subscribe to CNBC: [ Ссылка ]
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.
Connect with CNBC News Online
Get the latest news: [ Ссылка ]
Follow CNBC on LinkedIn: [ Ссылка ]
Follow CNBC News on Instagram: [ Ссылка ]
Follow CNBC News on Facebook: [ Ссылка ]
Follow CNBC on Threads: [ Ссылка ]
Follow CNBC News on X: [ Ссылка ]
Follow CNBC on WhatsApp: [ Ссылка ]
[ Ссылка ]
#CNBC
#CNBCTV
